Asset Details
Do you wish to reserve the book?
Malnutrition risk at solid tumor diagnosis: the malnutrition screening tool in a large US cancer institute
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Malnutrition risk at solid tumor diagnosis: the malnutrition screening tool in a large US cancer institute
Do you wish to request the book?
Malnutrition risk at solid tumor diagnosis: the malnutrition screening tool in a large US cancer institute
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Malnutrition risk at solid tumor diagnosis: the malnutrition screening tool in a large US cancer institute
2022
Overview
Background
In cancer, malnutrition is common and negatively impacts tolerance and outcomes of anti-tumor therapies. The aim of this study was to evaluate the prevalence of malnutrition risk and compare the clinicodemographic features between those with high malnutrition screening tool (MST) scores (i.e., ≥ 2 of 5 = high risk for malnutrition, H-MST) to low scores (L-MST).
Methods
A cohort of 3585 patients (May 2017 through December 2018), who completed the MST at least once at the time of diagnosis of any stage solid tumor, were analyzed. Logistic regression tested for associations between clinicodemographic factors, symptom scores, and H-MST prevalence.
Results
The median age was 64 years (25–75 IQR, 55–72), with 62% females and 81% White. Most common tumor primary sites were breast (28%), gastrointestinal (GI) (21%), and thoracic (13%). Most had non-metastatic disease (80%). H-MST was found in 28%—most commonly in upper (58%) and lower GI (42%), and thoracic (42%) tumors. L-MST was most common in breast (90%). Multivariable regression confirmed that Black race (OR 1.9, 95% CI 1.5–2.4,
p
= < 0.001), cancer primary site (OR 1.6–5.7,
p
= < 0.001), stage IV disease (OR 1.8, 95% CI 1.4–2.2,
p
= < 0.001), low BMI (OR 4.2, 95% CI 2.5–6.9
p
= < 0.001), and higher symptom scores were all independently associated with H-MST.
Conclusions
Twenty-eight percent of solid tumor oncology patients at diagnosis were at high risk of malnutrition. Patients with breast cancer rarely had malnutrition risk at diagnosis. Significant variation was found in malnutrition risk by cancer site, stage, race, and presence of depression, distress, fatigue, and trouble eating/swallowing.
